Abemaciclib is a cyclin-dependent 4/6 inhibitor approved by FDA in 2017 and by EMA in 2018 for treatment of hormone receptors positive, HER2 negative metastatic breast cancer in association with endocrine therapy. In 2019 FDA warned for a rare but severe lung inflammation possibly related to CDK 4/6 inhibitors. At the end of 2019 the world comes to know to a new corona virus causing potential fatal lung injury. Here we report three different cases of interstitial lung disease in patients treated with Abemaciclib during SARS-CoV-2 pandemic at Modena Cancer Center.

Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series / Barbolini, Monica; Omarini, Claudia; Toss, Angela; Cortesi, Giulia; Fiorani, Claudia; Piombino, Claudia; Dominici, Massimo; Piacentini, Federico. - In: CLINICS IN ONCOLOGY. - ISSN 2474-1663. - 5:(2020), pp. 1760-1761.

Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series.

Barbolini Monica;Omarini Claudia;Toss Angela;Cortesi Giulia;Piombino Claudia;Dominici Massimo;Piacentini Federico
2020

Abstract

Abemaciclib is a cyclin-dependent 4/6 inhibitor approved by FDA in 2017 and by EMA in 2018 for treatment of hormone receptors positive, HER2 negative metastatic breast cancer in association with endocrine therapy. In 2019 FDA warned for a rare but severe lung inflammation possibly related to CDK 4/6 inhibitors. At the end of 2019 the world comes to know to a new corona virus causing potential fatal lung injury. Here we report three different cases of interstitial lung disease in patients treated with Abemaciclib during SARS-CoV-2 pandemic at Modena Cancer Center.
2020
14-dic-2020
5
1760
1761
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series / Barbolini, Monica; Omarini, Claudia; Toss, Angela; Cortesi, Giulia; Fiorani, Claudia; Piombino, Claudia; Dominici, Massimo; Piacentini, Federico. - In: CLINICS IN ONCOLOGY. - ISSN 2474-1663. - 5:(2020), pp. 1760-1761.
Barbolini, Monica; Omarini, Claudia; Toss, Angela; Cortesi, Giulia; Fiorani, Claudia; Piombino, Claudia; Dominici, Massimo; Piacentini, Federico
File in questo prodotto:
File Dimensione Formato  
ILD and abemaciclib.pdf

Open access

Descrizione: Articolo principale
Tipologia: Versione pubblicata dall'editore
Dimensione 517.74 kB
Formato Adobe PDF
517.74 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1240956
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact